Recro Pharma Inc (NASDAQ:REPH) – Oppenheimer issued their FY2017 EPS estimates for Recro Pharma in a report issued on Tuesday. Oppenheimer analyst D. Archila expects that the specialty pharmaceutical company will post earnings per share of ($2.43) for the year. Oppenheimer has a “Outperform” rating and a $19.00 price target on the stock. Oppenheimer also issued estimates for Recro Pharma’s Q4 2017 earnings at ($1.07) EPS, Q1 2018 earnings at ($0.52) EPS, Q2 2018 earnings at ($0.54) EPS, Q3 2018 earnings at ($0.79) EPS, Q4 2018 earnings at ($0.68) EPS, FY2018 earnings at ($2.57) EPS, FY2019 earnings at ($0.97) EPS, FY2020 earnings at $0.73 EPS, FY2021 earnings at $2.23 EPS and FY2022 earnings at $2.80 EPS.
Several other research firms have also commented on REPH. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Piper Jaffray Companies restated a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a research report on Friday, October 27th. CIBC began coverage on Recro Pharma in a research report on Wednesday. They set an “outperform” rating and a $19.00 price target for the company. Finally, UBS Group began coverage on Recro Pharma in a research report on Tuesday, February 13th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $13.75.
A number of large investors have recently added to or reduced their stakes in the stock. JT Stratford LLC boosted its holdings in Recro Pharma by 7.8% in the fourth quarter. JT Stratford LLC now owns 112,265 shares of the specialty pharmaceutical company’s stock valued at $1,038,000 after purchasing an additional 8,120 shares during the period. Lyon Street Capital LLC purchased a new position in Recro Pharma in the fourth quarter valued at $3,362,000. Two Sigma Investments LP purchased a new position in Recro Pharma in the fourth quarter valued at $164,000. Deutsche Bank AG boosted its holdings in Recro Pharma by 141.6% in the fourth quarter. Deutsche Bank AG now owns 30,446 shares of the specialty pharmaceutical company’s stock valued at $281,000 after purchasing an additional 17,845 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Recro Pharma by 23.4% in the fourth quarter. Renaissance Technologies LLC now owns 122,000 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after purchasing an additional 23,100 shares during the period. Hedge funds and other institutional investors own 61.88% of the company’s stock.
In related news, major shareholder Healthcare Master Fun Broadfin sold 100,000 shares of Recro Pharma stock in a transaction on Tuesday, December 5th. The stock was sold at an average price of $10.00, for a total value of $1,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of Recro Pharma stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $8.88, for a total value of $115,120.32. Following the completion of the transaction, the insider now owns 734,269 shares of the company’s stock, valued at $6,520,308.72. The disclosure for this sale can be found here. Over the last quarter, insiders sold 860,414 shares of company stock valued at $8,289,916. 21.60% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2018/02/18/brokers-set-expectations-for-recro-pharma-incs-fy2017-earnings-reph.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.